Chantelle D. Ankerman

Associate

Contact

Practice Areas

Chantelle Ankerman is an associate in Axinn’s Intellectual Property group. Her practice focuses on intellectual property litigation and counseling, particularly in the fields of pharmaceuticals, biotechnology, and medical devices. Chantelle has litigated Hatch-Waxman Paragraph IV patent infringement suits and Section 337 Investigations at the International Trade Commission, as well as complex antitrust and commercial litigation matters. Chantelle also has experience drafting and prosecuting U.S. and international patent applications in relation to an assortment of medical device, electrical, mechanical, and computer technologies.

Chantelle D. Ankerman

Associate

Hartford

Contact

Practice Areas

Download PDF Download V-Card

Chantelle received her BS in Physiology and Neurobiology from the University of Connecticut, and her JD from the University of Connecticut School of Law, which she attended on a Dean’s Merit Scholarship. While at UConn Law, she served as a symposium editor for the Connecticut Law Review and earned CALI Awards for Excellence in Human Rights and Intellectual Property Law and in Admiralty Law.

Experience

Representing Norwich Pharmaceuticals Inc. in a patent infringement action filed by Salix Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Bausch Health Ireland Ltd., and Alfasigma S.P.A. The suit sought to stop Norwich from gaining approval to market a rifaximin 550 mg tablet, a generic of Salix’s Xifaxan^®. Obtained judgment of invalidity on many of the asserted claims, which halted the trading of plaintiff’s parent company’s stock after it plummeted following the decision. Axinn is currently handling the appeal in the Federal Circuit Court.
Defended generic pharmaceutical company in Hatch-Waxman case concerning 18 patents and over 400 patent claims regarding Takeda’s (previously Shire’s) brand lisdexamphetamine capsules, Vyvanse^®.

Represented Alvogen in a patent infringement action filed by Novo Nordisk, Inc., and Novo Nordisk A/S. Alvogen sought to be among the first manufacturers to market a generic equivalent of Novo’s blockbuster brand semaglutide injection, Ozempic^®, in the United States.
Defense of Thales against the patent infringement action brought by Philips relating to 3G and 4G LTE wireless communication technology in an ITC investigation and obtained final determination of no violation on multiple grounds.
Represented plaintiff in a breach of contract and fraud litigation involving a $20 million asset acquisition. The court denied defendants’ motion for summary judgment on both the breach of contract and fraud claims, allowing the case to proceed to trial, while granting plaintiff’s motion for summary judgment dismissing defendants’ counterclaims.

Honors

Best Lawyers, “Ones to Watch” (2025)
ANDA Litigation Intelligence Report: Top 250 Best Performing ANDA Attorneys for Representing Defendants (2023)
ANDA Litigation Intelligence Report: Top 250 Most Active ANDA Attorneys for Representing Defendants (2023)

University of Connecticut School of Law

Dean’s Merit Scholarship
CALI Awards for Excellence in Human Rights and Intellectual Property Law, Admiralty Law

Education

JD – University of Connecticut School of Law (2017)
BS, cum laude – University of Connecticut (2004)

Admissions

Connecticut
U.S. Patent and Trademark Office
U.S. District Court District of Connecticut
U.S. Court of Appeals for the Federal Circuit

Quotes

The team operates at a high level.

Chambers USA

Profile

Experience

Representing Norwich Pharmaceuticals Inc. in a patent infringement action filed by Salix Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Bausch Health Ireland Ltd., and Alfasigma S.P.A. The suit sought to stop Norwich from gaining approval to market a rifaximin 550 mg tablet, a generic of Salix’s Xifaxan^®. Obtained judgment of invalidity on many of the asserted claims, which halted the trading of plaintiff’s parent company’s stock after it plummeted following the decision. Axinn is currently handling the appeal in the Federal Circuit Court.
Defended generic pharmaceutical company in Hatch-Waxman case concerning 18 patents and over 400 patent claims regarding Takeda’s (previously Shire’s) brand lisdexamphetamine capsules, Vyvanse^®.

Represented Alvogen in a patent infringement action filed by Novo Nordisk, Inc., and Novo Nordisk A/S. Alvogen sought to be among the first manufacturers to market a generic equivalent of Novo’s blockbuster brand semaglutide injection, Ozempic^®, in the United States.
Defense of Thales against the patent infringement action brought by Philips relating to 3G and 4G LTE wireless communication technology in an ITC investigation and obtained final determination of no violation on multiple grounds.
Represented plaintiff in a breach of contract and fraud litigation involving a $20 million asset acquisition. The court denied defendants’ motion for summary judgment on both the breach of contract and fraud claims, allowing the case to proceed to trial, while granting plaintiff’s motion for summary judgment dismissing defendants’ counterclaims.

Honors

Education

Admissions

The team operates at a high level.

Chambers USA

The team operates at a high level.

Chambers USA

News & Insights

View all Insights

August 15, 2024

Axinn Attorneys Named to Best Lawyers 2025

Axinn is pleased to announce that eleven attorneys have been named to the 2025 list of “Best Lawyers in America” and sixteen attorneys have been named to the list of “Ones to Watch.” Two attorneys have been named “Lawyer of the Year” in their individual practice areas. Best Lawyers® compiles their lists of outstanding attorneys by conducting peer-review surveys in which tens of thousands of leading lawyers confidentially evaluate their professional peers.

Awards & Recognitions

Antitrust

March 6, 2024

Indefinite Contradiction or Inartful Claim Narrowing?

Earlier today the Federal Circuit in Maxell v. Amperex, No. 23-1194, vacated a District Court’s indefiniteness determination after...

Axinn Viewpoints

Intellectual Property

February 21, 2024

“Inelegant” Language Does Not an Indefinite Claim Term Make

To follow up on my February 6, 2024 post, Federal Circuit Judges Prost, Taranto, and Chen heard oral argument on February 9, 2024 in...

Axinn Viewpoints

Intellectual Property

August 12, 2022

Litigator of the Week Honors for Patent Trial Success

Matthew Murphy was honored in The American Lawyer’s “Litigator of the Week” column for Axinn’s trial success on behalf of Alvogen affiliate Norwich Pharmaceuticals in its defense of patent claims asserted by Bausch Health subsidiary Salix Pharmaceuticals. The column noted that the “key ruling” for Norwich, which is seeking to market a generic version of Salix’s blockbuster product Xifaxan®, led to a halt in trading of Bausch Health stock, which dropped more than 50% after news of the judge’s decision. The “Litigator of the Week” feature focuses on cases with “high stakes, long odds,” and “an impact, where the outcome matters to more than just the parties involved.”

News

Intellectual Property

August 10, 2022

Axinn Achieves Trial Success for Norwich Pharmaceuticals as it Seeks to Market a Generic of Xifaxan®

On behalf of its client Norwich Pharmaceuticals, an affiliate of Alvogen, Axinn succeeded in proving at trial that two sets of patents directed to a method of treatment (IBS-D) and composition of matter (polymorph) were invalid as obvious. Norwich is seeking approval to market a rifaximin 550 mg tablet, a generic version of Salix’s Xifaxan®, which is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

News

Intellectual Property

July 6, 2022

Commission Affirms Axinn’s ITC Victory for Thales

Axinn represented Thales DIS AIS, a leading developer of cellular communication modules used in a variety of products such as CPAP machines, vehicle monitoring, wireless meters, and data terminals, in an ITC investigation that was instituted in January of 2021. Despite Thales’ efforts to negotiate a fair, reasonable, and non-discriminatory (FRAND) license, Philips filed a complaint at the ITC, seeking to exclude Thales modules from the U.S. market, asserting four patents that are allegedly essential to 3G/4G standards. Following a 5-day evidentiary hearing in October of 2021, the ALJ issued a 300+ page determination of no violation in April 2022 on multiple grounds, including findings that all of the asserted claims of the four patents asserted at the ITC are not infringed and that three of the four asserted patents are also invalid. On July 6, 2022, the Commission affirmed the determination of no violation and terminated the investigation. The Axinn team included partners Denise Plunkett, and Michael Keeley, counsel Michael O’Mara, Thomas Hedemann, and associates Chantelle Ankerman, Ramya Auroprem, Rebecca Clegg, and Ricardo Camposanto.

News

Antitrust

News & Insights

Related People

Matthew J. Becker

Intellectual Property Practice Chair

Matt Becker is the Chair of the Intellectual Property practice and has over 25 years of experience trying and litigating a diverse range of patent infringement and trade secret cases. He has tried numerous high-stakes cases to both courts and juries.

Learn more

Aziz Burgy

Partner

Experienced Hatch-Waxman Patent Litigator

As a first-chair trial attorney for major brand and generic drug companies in over 80 Hatch-Waxman Act cases, Aziz Burgy brings a wealth of experience to pharmaceutical patent litigation. Aziz has been honored among the top 3% of ANDA litigators in Patexia intelligence reports and is consistently recognized by various publications, including IAM Patent 1000, LMG Life Sciences, and Benchmark Litigation. Aziz also advises clients on FDA matters and with product selection to help clients target products for acquisition or development.

Learn more

Ricardo Camposanto

Associate

Ricardo Camposanto is an associate in Axinn’s Intellectual Property group. His practice is focused on patent litigation, including service of clients in the fields of pharmaceuticals, medical devices, and wireless technologies. In addition to his extensive trial court experience, he has also practiced before the Federal and Fourth Circuits, Patent Trial and Appeals Board, and International Trade Commission. His practice further includes counseling services related to patent portfolio evaluation, drafting of licensing agreements and other contracts, and pro bono work related to local business disputes and Section 1983 civil rights litigation.

Learn more

Rebecca L. Clegg

Counsel

Rebecca Clegg's practice focuses on complex intellectual property litigation and counseling, particularly in the fields of medical devices, pharmaceuticals, biotechnology, and semiconductors. Rebecca regularly litigates medical device and Hatch-Waxman Paragraph IV patent infringement suits. She also has experience representing clients in commercial litigation cases.

Learn more